A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Number of Patients by Patient Characteristics

Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.

Time frame: Baseline

Age

Time frame: Baseline

Progression-free Survival (PFS) From Index Date

Time from the applicable index date until progression or death from any cause. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

Time frame: Up to approximately 5 years

PFS From Initiation of First Post-index Therapy, in Patients With ≥1 Post-index Therapy

Time from the initiation of first post-index therapy until progression or death from any cause.

Time frame: Up to approximately 5 years

Overall Survival (OS) From Index Date

Time from the applicable index date until death from any cause. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.

Time frame: Up to approximately 5 years

OS From Initiation of First Post-index Therapy, in Those With ≥1 Post-index Therapy

Time from initiation of first post-index therapy until death from any cause.

Time frame: Up to approximately 5 years

Among Patients With ≥1 Post-index Therapy, Number of Patients With a Reduction in PSA Level

Reduction in PSA level categorized as follows: * ≥50% (PSA50) reduction in PSA level * ≥80% (PSA80) reduction in PSA level * ≥90% (PSA90) reduction in PSA level

Time frame: Up to approximately 5 years

Among Patients With ≥1 Post-index Therapy, Number of Patients With PSA <0.2 ng/mL on First Post-index Therapy

Time frame: Up to approximately 5 years